アンチセンスおよびRNAi治療薬の世界市場規模調査＆予測、技術別、用途別、投与経路別、地域別分析、2023-2030年

アンチセンスおよびRNAi治療薬の世界市場は、2022年に約36億9,000万米ドルと評価され、予測期間2023～2030年には18.72％以上の健全な成長率で成長すると予測されています。

アンチセンスおよびRNA干渉（RNAi）治療薬は、分子医学分野における革新的なアプローチであり、RNAレベルで疾患に関与する特定の遺伝子を標的とすることを目的としています。アンチセンス治療では、合成核酸分子を用いて相補的なmRNA配列と結合させることで、遺伝子発現を阻害したり、スプライシングパターンを変化させたりします。このアプローチはタンパク質の産生を調節することができるため、遺伝子疾患やウイルス感染を含む様々な疾患の治療に有用である可能性があります。一方、RNAi治療薬は、特定のmRNA分子を分解する天然の細胞機構を利用し、標的遺伝子の発現を効果的に抑制します。アンチセンスおよびRNAi治療薬市場は、遺伝性疾患の罹患率の増加、アンチセンスおよびRNAi治療薬のパイプラインの拡大、治療薬開発への投資や資金の増加などの要因により拡大しています。

アンチセンス技術は、遺伝子発現を操作する有効性で知られ、様々な病状に対する成功した治療オプションとして浮上しています。企業はアンチセンスとRNAi技術がもたらす機会を捉え、この領域での進歩を推進しています。例えば、2023年1月、Agilent Technologies Inc.社は、治療用核酸の製造能力を強化するために7億2,500万米ドルの巨額投資を行った。この能力拡大により、同社は低分子干渉RNA（siRNA）やアンチセンス分子の旺盛な需要に対応できるようになります。同様に、2023年3月には、急成長中のバイオテクノロジー企業であるSwitch Therapeuticsが、5,200万米ドルの資金調達を受け、デビューを飾った。条件付活性化siRNA（CASi）と呼ばれる革新的な技術を活用し、同社は細胞選択的遺伝子ノックダウンプラットフォームを構築し、次世代のRNA干渉（RNAi）療法の進化を推進する態勢を整えました。これらの進歩は、市場における技術革新の顕著な急増を示すものです。加えて、個別化医療の進展、共同研究やパートナーシップの増加が、市場成長に新たな機会をもたらす要因となっています。しかし、アンチセンスおよびRNAi治療薬のコストが高いことが、2023-2030年の予測期間を通じて市場の成長を阻害しています。

アンチセンスおよびRNAi治療薬の世界市場調査において考慮した主要地域には、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカが含まれます。北米は2022年に最大の市場シェアで市場を独占しました。この地域には、高度なアンチセンスおよびRNAi治療薬が存在し、洗練されたヘルスケアインフラが整備されています。この強固なインフラは、希少疾患の早期スクリーニングを促進し、結果としてアンチセンスおよびRNAi治療薬の需要増加に拍車をかけています。欧州は予測期間中に最も速い速度で成長すると予想されています。アンチセンスおよびRNAi治療薬に特化した複数の企業が急成長していることが、予測期間を通じてこの地域の成長を促進する見通しです。これらの企業は、製品スペクトルとビジネスの道を広げるために様々な試みに積極的に取り組んでいます。例えば、米国を拠点とするSciNeuro Pharmaceuticals社は、2023年3月にSecarna Pharmaceuticals GmbH &Co.KGとパートナーシップを締結しました。この提携は、中枢神経系における極めて重要な疾患メカニズムをターゲットとする革新的なアンチセンス・オリゴヌクレオチド（ASO）療法を開発することを目的としています。その結果、欧州市場に対するさまざまな地域の業界利害関係者の注目が高まっており、当面の地域拡大が活性化すると予測されます。

本調査の目的は、近年のさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 世界のアンチセンスおよびRNAi治療薬市場の定義と範囲

• 調査目的
• 市場の定義と範囲
  • 産業の進化
  • 調査範囲
• 調査対象年
• 通貨換算レート

第3章 アンチセンスおよびRNAi治療薬の世界市場力学

• アンチセンスおよびRNAi治療薬市場の影響分析（2020-2030年）
  • 市場促進要因
    • 遺伝性疾患の増加
    • アンチセンスおよびRNAi医薬品のパイプラインの増加
    • 治療薬開発への投資と資金調達の増加
  • 市場の課題
    • アンチセンスおよびRNAi治療薬の高コスト
  • 市場機会
    • 個別化医療の進展
    • 共同研究やパートナーシップの増加

第4章 アンチセンスおよびRNAi治療薬の世界市場産業分析

• ポーターのファイブフォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターのファイブフォース影響分析
• PEST分析
• 主な投資機会
• 主要成功戦略
• COVID-19影響分析
• 破壊的動向
• 業界専門家の視点
• アナリストの結論・提言

第5章 アンチセンスおよびRNAi治療薬の世界市場：技術別

• 市場スナップショット
• アンチセンスおよびRNAi治療薬の世界市場：技術別、実績 - ポテンシャル分析
• アンチセンスおよびRNAi治療薬の世界市場：技術別推定・予測 2020-2030年
• アンチセンスおよびRNAi治療薬市場：サブセグメント分析
  • RNA干渉
  • アンチセンスRNA

第6章 アンチセンスおよびRNAi治療薬の世界市場：用途別

• 市場スナップショット
• アンチセンスおよびRNAi治療薬の世界市場：用途別、実績 - ポテンシャル分析
• アンチセンスおよびRNAi治療薬の世界市場：用途別推定・予測 2020-2030年
• アンチセンスおよびRNAi治療薬市場：サブセグメント分析
  • 遺伝子疾患
  • がん
  • 感染症
  • 神経変性疾患
  • 代謝性心疾患および腎疾患
  • 眼疾患
  • 呼吸器疾患
  • 皮膚疾患

第7章 アンチセンスおよびRNAi治療薬の世界市場：投与経路別

• 市場スナップショット
• アンチセンスおよびRNAi治療薬の世界市場：投与ルート別、実績 - ポテンシャル分析
• アンチセンスおよびRNAi治療薬の世界市場：投与ルート別推定・予測 2020-2030年
• アンチセンスおよびRNAi治療薬市場：サブセグメント分析
  • 静脈注射
  • 髄腔内注射
  • 皮下注射
  • その他の投与方法

第8章 アンチセンスおよびRNAi治療薬の世界市場：地域別分析

• 主要国
• 主な新興国
• アンチセンスおよびRNAi治療薬市場、：地域別市場スナップショット
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカト
  • ブラジル
  • メキシコ
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • その他中東とアフリカ

第9章 競合情報

• 主要企業のSWOT分析
• 主要市場戦略
• 企業プロファイル
  • GSK plc
    • 主要情報
    • 概要
    • 財務（データの入手可能性によります）
    • 製品概要
    • 最近の動向
  • Olix Pharmaceuticals, Inc.
  • Sanofi S.A
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma
  • Benitec Biopharma Inc.
  • Silence Therapeutics
  • Ionis Pharmaceuticals, Inc
  • Sarepta Therapeutics
  • Percheron Therapeutics Limited

第10章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • 検証
  • 出版
• 調査属性
• 調査前提条件

LIST OF TABLES

• TABLE 1. Global Antisense and RNAi therapeutics Market, report scope
• TABLE 2. Global Antisense and RNAi therapeutics Market estimates & forecasts by Region 2020-2030 (USD Billion)
• TABLE 3. Global Antisense and RNAi therapeutics Market estimates & forecasts by Technology 2020-2030 (USD Billion)
• TABLE 4. Global Antisense and RNAi therapeutics Market estimates & forecasts by Application 2020-2030 (USD Billion)
• TABLE 5. Global Antisense and RNAi therapeutics Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
• TABLE 6. Global Antisense and RNAi therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 7. Global Antisense and RNAi therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 8. Global Antisense and RNAi therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 9. Global Antisense and RNAi therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 10. Global Antisense and RNAi therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 11. Global Antisense and RNAi therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 12. Global Antisense and RNAi therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 13. Global Antisense and RNAi therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 14. Global Antisense and RNAi therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 15. Global Antisense and RNAi therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 16. U.S. Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 17. U.S. Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 18. U.S. Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 19. Canada Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 20. Canada Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 21. Canada Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 22. UK Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 23. UK Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 24. UK Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 25. Germany Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 26. Germany Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 27. Germany Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 28. France Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 29. France Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 30. France Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 31. Italy Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 32. Italy Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 33. Italy Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 34. Spain Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 35. Spain Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 36. Spain Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 37. RoE Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 38. RoE Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 39. RoE Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 40. China Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 41. China Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 42. China Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 43. India Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 44. India Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 45. India Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 46. Japan Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 47. Japan Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 48. Japan Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 49. South Korea Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 50. South Korea Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 51. South Korea Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 52. Australia Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 53. Australia Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 54. Australia Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 55. RoAPAC Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 56. RoAPAC Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 57. RoAPAC Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 58. Brazil Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 59. Brazil Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 60. Brazil Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 61. Mexico Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 62. Mexico Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 63. Mexico Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 64. RoLA Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 65. RoLA Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 66. RoLA Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 67. Saudi Arabia Antisense and RNAi therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 68. South Africa Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 69. RoMEA Antisense and RNAi therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 70. List of secondary sources, used in the study of global Antisense and RNAi therapeutics Market
• TABLE 71. List of primary sources, used in the study of global Antisense and RNAi therapeutics Market
• TABLE 72. Years considered for the study
• TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

• FIG 1. Global Antisense and RNAi therapeutics Market, research methodology
• FIG 2. Global Antisense and RNAi therapeutics Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Antisense and RNAi therapeutics Market, key trends 2022
• FIG 5. Global Antisense and RNAi therapeutics Market, growth prospects 2023-2030
• FIG 6. Global Antisense and RNAi therapeutics Market, porters 5 force model
• FIG 7. Global Antisense and RNAi therapeutics Market, pest analysis
• FIG 8. Global Antisense and RNAi therapeutics Market, value chain analysis
• FIG 9. Global Antisense and RNAi therapeutics Market by segment, 2020 & 2030 (USD Billion)
• FIG 10. Global Antisense and RNAi therapeutics Market by segment, 2020 & 2030 (USD Billion)
• FIG 11. Global Antisense and RNAi therapeutics Market by segment, 2020 & 2030 (USD Billion)
• FIG 12. Global Antisense and RNAi therapeutics Market by segment, 2020 & 2030 (USD Billion)
• FIG 13. Global Antisense and RNAi therapeutics Market by segment, 2020 & 2030 (USD Billion)
• FIG 14. Global Antisense and RNAi therapeutics Market, regional snapshot 2020 & 2030
• FIG 15. North America Antisense and RNAi therapeutics Market 2020 & 2030 (USD Billion)
• FIG 16. Europe Antisense and RNAi therapeutics Market 2020 & 2030 (USD Billion)
• FIG 17. Asia pacific Antisense and RNAi therapeutics Market 2020 & 2030 (USD Billion)
• FIG 18. Latin America Antisense and RNAi therapeutics Market 2020 & 2030 (USD Billion)
• FIG 19. Middle East & Africa Antisense and RNAi therapeutics Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Antisense and RNAi therapeutics Market is valued approximately at USD 3.69 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 18.72% over the forecast period 2023-2030. Antisense and RNA interference (RNAi) therapeutics represent innovative approaches in the field of molecular medicine, aiming to target specific genes implicated in diseases at the level of RNA. Antisense therapy involves the use of synthetic nucleic acid molecules to bind complementary mRNA sequences, thereby inhibiting gene expression or altering splicing patterns. This approach can modulate protein production, making it potentially useful for treating various conditions, including genetic disorders and viral infections. On the other hand, RNAi therapeutics harness the natural cellular machinery to degrade specific mRNA molecules, effectively silencing the expression of target genes. The Antisense and RNAi therapeutics market is expanding because of factors such as increasing incidence of genetic disorders, growing pipeline of antisense and RNAi drugs and increasing investment and funding for therapeutics development.

Antisense technology, known for its efficacy in manipulating gene expression, has emerged as a successful treatment option for various medical conditions. Companies are seizing the opportunities presented by antisense and RNAi technologies, driving advancements in this domain. For instance, in January 2023, Agilent Technologies Inc. committed a significant investment of USD 725 million to bolster the manufacturing capacity of therapeutic nucleic acids. This expanded capability is poised to enable the company to meet the robust demand for small interfering RNA (siRNA) and antisense molecules. Similarly, In March 2023, Switch Therapeutics, a burgeoning biotechnology firm, unveiled its debut after securing USD 52 million in financing. Leveraging its innovative technology called Conditionally Activated siRNA (CASi), the company has crafted a cell-selective gene knockdown platform poised to propel the evolution of the next generation of RNA interference (RNAi) therapies. These advancements signal a notable surge in innovation within the market. In addition, rising development of personalized medicine, increased collaboration and partnerships are some factors creating new opportunities to the market growth. However, the high cost of Antisense and RNAi therapeutics stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Antisense and RNAi therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share. The presence of advanced antisense and RNAi therapeutics along with presence of sophisticated healthcare infrastructure in the region. This robust infrastructure has facilitated an upswing in the early screening of rare diseases, consequently fueling an increased demand for antisense and RNAi therapeutics. Europe is expected to grow at the fastest rate during the forecast period. The burgeoning presence of multiple enterprises dedicated to antisense and RNAi therapeutics is poised to propel regional growth throughout the forecast period. These entities are actively engaging in various endeavors to broaden their product spectrum and avenues for business. For example, in March 2023, SciNeuro Pharmaceuticals, a U.S.-based firm, entered into a partnership with Secarna Pharmaceuticals GmbH & Co. KG, headquartered in Europe. This collaboration aims to develop innovative antisense oligonucleotide (ASO) therapies targeting pivotal disease mechanisms in the Central Nervous System. Consequently, the escalating attention from industry stakeholders in different geographical spheres towards the European market is projected to invigorate regional expansion in the foreseeable future.

Major market player included in this report are:

• GSK plc
• Olix Pharmaceuticals, Inc.
• Sanofi S.A
• Alnylam Pharmaceuticals, Inc.
• Arbutus Biopharma
• Benitec Biopharma Inc.
• Silence Therapeutics
• Ionis Pharmaceuticals, Inc
• Sarepta Therapeutics
• Percheron Therapeutics Limited

Recent Developments in the Market:

• In August 2023, Sirnaomics Ltd disclosed the successful conclusion of the phase I clinical study for STP707, an RNAi therapeutic designed to address various solid tumors.
• In July 2023, Alnylam Pharmaceuticals, Inc. forged a partnership with Roche to collaborate on the development and commercialization of zilebesiran, an investigational RNA interference (RNAi) therapeutic aimed at managing hypertension.

Global Antisense and RNAi therapeutics Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Technology, Application, Route of Administration, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Technology:

• RNA Interference
• Antisense RNA

By Application:

• Genetic Disease
• Cancer
• Infectious Disease
• Neurodegenerative Disorders
• Cardiometabolic & Renal Disorders
• Ocular Disorders
• Respiratory Disorders
• Skin Disorders

By Route of Administration:

• Intravenous Injections
• Intrathecal Injections
• Subcutaneous Injections
• Other Delivery Methods

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Antisense and RNAi therapeutics Market, by region, 2020-2030 (USD Billion)
  • 1.2.2. Antisense and RNAi therapeutics Market, by Technology, 2020-2030 (USD Billion)
  • 1.2.3. Antisense and RNAi therapeutics Market, by Application, 2020-2030 (USD Billion)
  • 1.2.4. Antisense and RNAi therapeutics Market, by Route of Administration, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Antisense and RNAi therapeutics Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Antisense and RNAi therapeutics Market Dynamics

• 3.1. Antisense and RNAi therapeutics Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing incidences of genetic disorders
    • 3.1.1.2. Growing pipeline of antisense and RNAi drugs
    • 3.1.1.3. Increasing investment and funding for therapeutics development
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Antisense and RNAi therapeutics
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rising development of personalized medicine
    • 3.1.3.2. Increased collaboration and partnerships

Chapter 4. Global Antisense and RNAi therapeutics Market: Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economic
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Antisense and RNAi therapeutics Market, by Technology

• 5.1. Market Snapshot
• 5.2. Global Antisense and RNAi therapeutics Market by Technology, Performance - Potential Analysis
• 5.3. Global Antisense and RNAi therapeutics Market Estimates & Forecasts by Technology 2020-2030 (USD Billion)
• 5.4. Antisense and RNAi therapeutics Market, Sub Segment Analysis
  • 5.4.1. RNA Interference
  • 5.4.2. Antisense RNA

Chapter 6. Global Antisense and RNAi therapeutics Market, by Application

• 6.1. Market Snapshot
• 6.2. Global Antisense and RNAi therapeutics Market by Application, Performance - Potential Analysis
• 6.3. Global Antisense and RNAi therapeutics Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 6.4. Antisense and RNAi therapeutics Market, Sub Segment Analysis
  • 6.4.1. Genetic Disease
  • 6.4.2. Cancer
  • 6.4.3. Infectious Disease
  • 6.4.4. Neurodegenerative Disorders
  • 6.4.5. Cardiometabolic & Renal Disorders
  • 6.4.6. Ocular Disorders
  • 6.4.7. Respiratory Disorders
  • 6.4.8. Skin Disorders

Chapter 7. Global Antisense and RNAi therapeutics Market, by Route of Administration

• 7.1. Market Snapshot
• 7.2. Global Antisense and RNAi therapeutics Market by Route of Administration, Performance - Potential Analysis
• 7.3. Global Antisense and RNAi therapeutics Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
• 7.4. Antisense and RNAi therapeutics Market, Sub Segment Analysis
  • 7.4.1. Intravenous Injections
  • 7.4.2. Intrathecal Injections
  • 7.4.3. Subcutaneous Injections
  • 7.4.4. Other Delivery Methods

Chapter 8. Global Antisense and RNAi therapeutics Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Antisense and RNAi therapeutics Market, Regional Market Snapshot
• 8.4. North America Antisense and RNAi therapeutics Market
  • 8.4.1. U.S. Antisense and RNAi therapeutics Market
    • 8.4.1.1. Technology breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. Route of Administration breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Antisense and RNAi therapeutics Market
• 8.5. Europe Antisense and RNAi therapeutics Market Snapshot
  • 8.5.1. U.K. Antisense and RNAi therapeutics Market
  • 8.5.2. Germany Antisense and RNAi therapeutics Market
  • 8.5.3. France Antisense and RNAi therapeutics Market
  • 8.5.4. Spain Antisense and RNAi therapeutics Market
  • 8.5.5. Italy Antisense and RNAi therapeutics Market
  • 8.5.6. Rest of Europe Antisense and RNAi therapeutics Market
• 8.6. Asia-Pacific Antisense and RNAi therapeutics Market Snapshot
  • 8.6.1. China Antisense and RNAi therapeutics Market
  • 8.6.2. India Antisense and RNAi therapeutics Market
  • 8.6.3. Japan Antisense and RNAi therapeutics Market
  • 8.6.4. Australia Antisense and RNAi therapeutics Market
  • 8.6.5. South Korea Antisense and RNAi therapeutics Market
  • 8.6.6. Rest of Asia Pacific Antisense and RNAi therapeutics Market
• 8.7. Latin America Antisense and RNAi therapeutics Market Snapshot
  • 8.7.1. Brazil Antisense and RNAi therapeutics Market
  • 8.7.2. Mexico Antisense and RNAi therapeutics Market
• 8.8. Middle East & Africa Antisense and RNAi therapeutics Market
  • 8.8.1. Saudi Arabia Antisense and RNAi therapeutics Market
  • 8.8.2. South Africa Antisense and RNAi therapeutics Market
  • 8.8.3. Rest of Middle East & Africa Antisense and RNAi therapeutics Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. GSK plc
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. Olix Pharmaceuticals, Inc.
  • 9.3.3. Sanofi S.A
  • 9.3.4. Alnylam Pharmaceuticals, Inc.
  • 9.3.5. Arbutus Biopharma
  • 9.3.6. Benitec Biopharma Inc.
  • 9.3.7. Silence Therapeutics
  • 9.3.8. Ionis Pharmaceuticals, Inc
  • 9.3.9. Sarepta Therapeutics
  • 9.3.10. Percheron Therapeutics Limited

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption